Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDerrick van Beuge

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals testing impacts clinical outcomes in chronic lymphocytic leukemia, suggesting improved survival with genetic markers.

Key Points

  • Patients tested for genetic markers in chronic lymphocytic leukemia had longer time to next treatment, approximately 41.7 months versus 30.0 months for untested individuals.
  • Testing for TP53 mutation and IGHV was linked to survival improvements, with patients without testing showing 27% increased hazards of death.
  • Retrospective cohort study utilized electronic health records, focusing on patients with chronic lymphocytic leukemia starting frontline treatment.
  • Genetic marker testing might prompt the administration of novel therapies, supporting better clinical management of chronic lymphocytic leukemia.

Cite This Study

Derrick van Beuge (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85ehttps://doi.org/10.1182/blood-2025-3894
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)2025
  2. 2A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada2025
  3. 3Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project2025
  4. 4TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom2025
  5. 5Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma2025